ASKC852 / Aosaikang Pharma - LARVOL DELTA

[VIRTUAL] A novel TGF-βRI inhibitor ASKC852, possessing antitumor and PD-L1 synergistic effect activities (AACR 2021) - "Our data demonstrates ASK852 is a potent and highly selective TGF-βRI inhibitor. It effectively blocked the TGF-β-SMAD signal pathway, with anti-tumor effect in syngeneic mouse models. Pharmacokinetic profile and safety properties support ASKC852 as a potential anticancer agent for the clinical treatment of solid tumors."

IO biomarker • Breast Cancer • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • ITK • TGFB1

Aosaikang’s Category 1 immunomodulator under trial review in China (GBI Health) - "Beijing Aosaikang Pharmaceutical Co., Ltd (002755.SZ) announced that an investigational new drug (IND) filing for its Category 1 drug candidate ASKC852 has been accepted for review by the National Medical Products Administration in China. ASKC852 is a small-molecule immunomodulator co-developed by Wuxi Apptec that inhibits tumor epithelial-mesenchymal transition and metastasis, enhancing anti-tumor immune response in the tumor microenvironment, and inhibiting intratumoral angiogenesis in order to arrest the growth and progression of tumors."

Non-US regulatory • Oncology